Table 2.

Longitudinal follow-up of subjects

Transmission pair follow-up data				Seroconverter follow-up datad
Subject	DPSa	No. of viral NFLGb	Plasma VL (RNA copies/ml)c	Subject	DPSa	No. of viral NFLGb	Plasma VL (RNA copies/ml)c
Pair 2				S1	7	10	377,060
T2	14	10	290,040		13	10	1,912,200
R2	3	9	620,820		21	15	312,200
	7	9	2,498,840		44	10	32,630
Pair 3					68	10	232,050
T3	∼9 yr*	10	28,610		96	10	109,950
R3	25	10	472,810		127	10	45,590
	33	10	169,580		181	10	105,870
	40	12	117,310	S2	6	10	923
	53	10	71,230		12	10	1,049,870
	83	10	30,650		20	10	26,785,000
	116	11	32,430		42	9	665,680
	144	10	24,740		48	10	668,660
	200	10	19,460		56	14	124,000
	247	10	14,610		69	9	254,300
Pair 4					98	11	151,000
T4	3,343	10	40,600		151	10	242,940
	3,394	9	22,190		210	10	60,950
R4	13	10	2,804,000		273	10	51,120
	18	10	54,160		350	10	49,600
	26	10	29,180	S3	3	10	469,830
					11	9	>1,600,000
					15	10	42,810
					71	10	12,200
					99	9	14,170
					128	10	18,210
					196	10	70,780

^aDPS, days postonset of clinical symptoms, with the exception of the value for T3 (*).

^bNFLG, nearly full-length genome sequence.

^cVL, viral load.

^dNo transmitter identified.